BCMA chimeric antigen receptors
First Claim
Patent Images
1. A lentiviral vector comprising a left (5′
- ) lentiviral LTR wherein the promoter of the 5′
LTR is replaced with a CMV promoter;
a Psi (Ψ
) packaging signal;
a cPPT/FLAP;
a Rev response element (RRE);
a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a polynucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the polynucleotide sequence is set forth in SEQ ID NO;
10;
a right (3′
) lentiviral self-inactivating (SIN) LTR; and
a heterologous polyadenylation sequence.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.
66 Citations
15 Claims
-
1. A lentiviral vector comprising a left (5′
- ) lentiviral LTR wherein the promoter of the 5′
LTR is replaced with a CMV promoter;
a Psi (Ψ
) packaging signal;
a cPPT/FLAP;
a Rev response element (RRE);
a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a polynucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the polynucleotide sequence is set forth in SEQ ID NO;
10;
a right (3′
) lentiviral self-inactivating (SIN) LTR; and
a heterologous polyadenylation sequence. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- ) lentiviral LTR wherein the promoter of the 5′
Specification